Vermont is currently home to 208 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Burlington, Bennington, Berlin and White River Junction. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Southwestern Vermont Medical Center, Bennington, Vermont
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: University of Vermont Children's Hospital, Burlington, Vermont
Conditions: Bronchiolitis Acute Viral
Register for Updates
Fatty Acid Modulation of Brain Function in Older Adults
NCT06192407
Recruiting
In this crossover study, the investigtors will administer two experimental diets in a random order for one week, and each experimental diet will be preceded by a one-week, low fat control diet for a total four-week study period. The goal is to study how the fatty acid content of the diet affects brain functioning in healthy adults aged 65-75 years. One experimental diet will have a high palmitic acid (PA)/oleic acid (OA) ratio (HPA), typical of the North American diet. The other experimental die... Read More
Gender:
ALL
Ages:
Between 65 years and 75 years
Trial Updated:
05/06/2024
Locations: University of Vermont, Burlington, Vermont
Conditions: Aging
Register for Updates
LEMURS SSI: Evaluation of Behavioral Incentives
NCT06340841
Recruiting
The goal of this substudy is to determine if a brief single-session-intervention (SSI) coupled with different incentive strategies to support engaging in wellness-related activities.
Gender:
ALL
Ages:
Between 18 years and 20 years
Trial Updated:
03/30/2024
Locations: University of Vermont, Burlington, Vermont
Conditions: Incentives
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: The University of Vermont Health Network, Burlington, Vermont
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
NCT03997981
Recruiting
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer, or vincristine for lymphoma.. Demographic data, medical history, electronic PROs, ClinROs blood biomarkers including NF-L, PGx DNA analyses and Bedside-QST will be assessed at Baseline. The Observation Period will initiate with the first dose of chemotherapy and conclud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053
Recruiting
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: University of Vermont, Burlington, Vermont
Conditions: Huntington's Disease
Register for Updates
Multi-disciplinary Care for Brain Metastases
NCT06280300
Recruiting
This is a health services intervention study aimed at understanding the impact of intensive multi-disciplinary care compared with standard care on patient-reported symptom outcomes and prognostic awareness in patients with brain metastases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Brain Metastases, Adult
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Rural New England Health Study (Phase 2)
NCT05466331
Recruiting
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New England. The intervention aims to reach rural opioid injectors with HCV and to fill service gaps identified around access to syringe services and HCV testing and treatment, while limiting the burden on local partners. If effective, this mobile model of HCV telehealth integrate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Mobile Study Van, Bennington, Vermont
Conditions: Hepatitis C, Opioid Use Disorder, IV Drug Usage
Register for Updates
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
NCT05048875
Recruiting
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/09/2023
Locations: University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington, Vermont
Conditions: Dengue
Register for Updates
Exercise Capacity Before and After AF Ablation in Patients With HFpEF
NCT05376748
Recruiting
In a prospective, observational pilot study of patients scheduled for an atrial fibrillation (AF) ablation at the University of Vermont Medical Center the investigators will compare exercise capacity before and four months after AF ablation.
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
06/20/2023
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Register for Updates